85 related articles for article (PubMed ID: 12171263)
1. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland.
Bennett KE; Williams D; Feely J
Ir Med J; 2002 Jun; 95(6):169-72. PubMed ID: 12171263
[TBL] [Abstract][Full Text] [Related]
2. Regional variation in the prescribing for diabetes and use of secondary preventative therapies in Ireland.
Usher C; Bennett K; Feely J
Pharmacoepidemiol Drug Saf; 2005 Aug; 14(8):537-44. PubMed ID: 15818637
[TBL] [Abstract][Full Text] [Related]
3. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland.
Byrne M; Murphy AW
Ir Med J; 2002 Oct; 95(9):282; author reply 282-3. PubMed ID: 12470007
[No Abstract] [Full Text] [Related]
4. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities.
Gnavi R; Migliardi A; Demaria M; Petrelli A; Caprioglio A; Costa G
Eur J Public Health; 2007 Oct; 17(5):492-6. PubMed ID: 17303583
[TBL] [Abstract][Full Text] [Related]
5. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
Simpson E; Beck C; Richard H; Eisenberg MJ; Pilote L
Am Heart J; 2003 Mar; 145(3):438-44. PubMed ID: 12660666
[TBL] [Abstract][Full Text] [Related]
6. Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial.
Majumdar SR; Tsuyuki RT; McAlister FA
Am Heart J; 2007 Jan; 153(1):22.e1-8. PubMed ID: 17174632
[TBL] [Abstract][Full Text] [Related]
7. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Turley AJ; Roberts AP; Morley R; Thornley AR; Owens WA; de Belder MA
Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):231-4. PubMed ID: 18234766
[TBL] [Abstract][Full Text] [Related]
8. Prescribing for patients with diabetes in the community drug schemes.
Usher C; Creed L; Bennett K; Feely J
Ir Med J; 2006 Jun; 99(6):181-3. PubMed ID: 16921826
[TBL] [Abstract][Full Text] [Related]
9. Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey.
Sturm HB; van Gilst WH; Veeger N; Haaijer-Ruskamp FM
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):96-103. PubMed ID: 16528759
[TBL] [Abstract][Full Text] [Related]
10. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
11. Under-prescribing of cardiovascular therapies for diabetes in primary care.
Bennett KE; Williams D; Feely J
Eur J Clin Pharmacol; 2003 Apr; 58(12):835-41. PubMed ID: 12698311
[TBL] [Abstract][Full Text] [Related]
12. Drug secondary prevention in postmenopausal women with ischemic heart disease.
Zdrenghea D; Pop D; Sitar-Tăut A; Cebanu M; Zdrenghea V
Rom J Intern Med; 2009; 47(1):41-5. PubMed ID: 19886068
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a gender and age inequality in the prescribing of preventative cardiovascular therapies to the elderly in primary care.
Usher C; Bennett K; Feely J
Age Ageing; 2004 Sep; 33(5):500-2. PubMed ID: 15315919
[No Abstract] [Full Text] [Related]
14. Primary care prescribing patterns in Ireland after the publication of large hypertension trials.
Kabir Z; Feely J; Bennett K
Br J Clin Pharmacol; 2007 Sep; 64(3):381-5. PubMed ID: 17610535
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the effect on patient outcomes of appropriate and inappropriate use of beta-blockers as secondary prevention after myocardial infarction in a medicaid population.
Fernandes AW; Madhavan SS; Amonkar MM
Clin Ther; 2005 May; 27(5):630-45. PubMed ID: 15978313
[TBL] [Abstract][Full Text] [Related]
16. Statin prescribing in Australia: socioeconomic and sex differences. A cross-sectional study.
Stocks NP; Ryan P; McElroy H; Allan J
Med J Aust; 2004 Mar; 180(5):229-31. PubMed ID: 14984343
[TBL] [Abstract][Full Text] [Related]
17. [Reasons for the under-use of secondary prevention therapies in coronary patients over the age of 70 years].
Cournot M; Cambou JP; Quentzel S; Danchin N
Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S17-23. PubMed ID: 16411647
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.
Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C
J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867
[TBL] [Abstract][Full Text] [Related]
19. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
[TBL] [Abstract][Full Text] [Related]
20. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
Gulliford MC; Charlton J; Latinovic R
J Hum Hypertens; 2005 Feb; 19(2):111-7. PubMed ID: 15361893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
